Listing 1 - 2 of 2 |
Sort by
|
Choose an application
The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field.
Medicine --- melanoma --- invasion --- WNT5A --- MARCKS --- phosphorylation --- MANS peptide --- nanoparticles --- cell therapy --- tumor microenvironment --- sex/gender --- sex-hormones --- immunity --- microRNAs --- immunotherapy --- BRAF-mutant melanoma --- BRAF inhibitor --- mechanism of action --- targeted therapy --- tumour microenvironment --- plasmacytoid dendritic cells --- lactate dehydrogenase --- TLR --- interferon --- CXCL10 --- TPC2 --- HIPPO --- SOCE --- metastasis --- essential oils --- angiogenesis --- apoptosis --- uveal melanoma (UM) --- metastatic uveal melanoma (mUM) --- prognostication --- adjuvant therapy --- metastatic therapy --- metastatic dormancy --- liver-directed-therapies --- targeted-therapy --- combined therapy --- protein tyrosine phosphatase --- PTPs inhibitors --- melanoma immune infiltrate --- BRAF inhibitors --- microenvironment --- resistance --- therapy --- therapeutic resistance --- exosomes --- extracellular vesicles --- diagnosis --- prognosis --- ctDNA --- liquid biopsy --- prediction --- patient stratification --- BRAF --- arthralgia --- rheumatoid arthritis --- carbonic anhydrase --- hedgehog --- cyclopamine --- small molecules --- acetazolamide --- motility --- metalloproteinases --- FAK --- cancer --- mucosal melanoma --- nivolumab --- pembrolizumab --- ipilimumab --- radiotherapy --- cholinergic system --- acetylcholine --- muscarinic receptors --- nicotinic receptors --- melanoma metastasis --- ShcD adaptor protein --- amoeboid motility --- Rac1 --- DOCK4 --- melanoma PDX --- target therapy --- cancer stem cells --- slow cycling phenotype --- drug resistance --- OXPHOS --- lipid metabolism --- cancer associated fibroblast --- melanomagenesis --- biomarkers --- checkpoint inhibitor --- PD-1 --- melanoma markers --- cytokines --- machine learning --- Support Vector Machine --- principal component analysis --- BCL2L10 --- STAT3 --- cytotoxicity --- survival --- ABT-737 --- Bcl-2 family --- ML258 --- HuR --- MITF --- metastases --- siRNA --- melanoma --- invasion --- WNT5A --- MARCKS --- phosphorylation --- MANS peptide --- nanoparticles --- cell therapy --- tumor microenvironment --- sex/gender --- sex-hormones --- immunity --- microRNAs --- immunotherapy --- BRAF-mutant melanoma --- BRAF inhibitor --- mechanism of action --- targeted therapy --- tumour microenvironment --- plasmacytoid dendritic cells --- lactate dehydrogenase --- TLR --- interferon --- CXCL10 --- TPC2 --- HIPPO --- SOCE --- metastasis --- essential oils --- angiogenesis --- apoptosis --- uveal melanoma (UM) --- metastatic uveal melanoma (mUM) --- prognostication --- adjuvant therapy --- metastatic therapy --- metastatic dormancy --- liver-directed-therapies --- targeted-therapy --- combined therapy --- protein tyrosine phosphatase --- PTPs inhibitors --- melanoma immune infiltrate --- BRAF inhibitors --- microenvironment --- resistance --- therapy --- therapeutic resistance --- exosomes --- extracellular vesicles --- diagnosis --- prognosis --- ctDNA --- liquid biopsy --- prediction --- patient stratification --- BRAF --- arthralgia --- rheumatoid arthritis --- carbonic anhydrase --- hedgehog --- cyclopamine --- small molecules --- acetazolamide --- motility --- metalloproteinases --- FAK --- cancer --- mucosal melanoma --- nivolumab --- pembrolizumab --- ipilimumab --- radiotherapy --- cholinergic system --- acetylcholine --- muscarinic receptors --- nicotinic receptors --- melanoma metastasis --- ShcD adaptor protein --- amoeboid motility --- Rac1 --- DOCK4 --- melanoma PDX --- target therapy --- cancer stem cells --- slow cycling phenotype --- drug resistance --- OXPHOS --- lipid metabolism --- cancer associated fibroblast --- melanomagenesis --- biomarkers --- checkpoint inhibitor --- PD-1 --- melanoma markers --- cytokines --- machine learning --- Support Vector Machine --- principal component analysis --- BCL2L10 --- STAT3 --- cytotoxicity --- survival --- ABT-737 --- Bcl-2 family --- ML258 --- HuR --- MITF --- metastases --- siRNA
Choose an application
The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field.
melanoma --- invasion --- WNT5A --- MARCKS --- phosphorylation --- MANS peptide --- nanoparticles --- cell therapy --- tumor microenvironment --- sex/gender --- sex-hormones --- immunity --- microRNAs --- immunotherapy --- BRAF-mutant melanoma --- BRAF inhibitor --- mechanism of action --- targeted therapy --- tumour microenvironment --- plasmacytoid dendritic cells --- lactate dehydrogenase --- TLR --- interferon --- CXCL10 --- TPC2 --- HIPPO --- SOCE --- metastasis --- essential oils --- angiogenesis --- apoptosis --- uveal melanoma (UM) --- metastatic uveal melanoma (mUM) --- prognostication --- adjuvant therapy --- metastatic therapy --- metastatic dormancy --- liver-directed-therapies --- targeted-therapy --- combined therapy --- protein tyrosine phosphatase --- PTPs inhibitors --- melanoma immune infiltrate --- BRAF inhibitors --- microenvironment --- resistance --- therapy --- therapeutic resistance --- exosomes --- extracellular vesicles --- diagnosis --- prognosis --- ctDNA --- liquid biopsy --- prediction --- patient stratification --- BRAF --- arthralgia --- rheumatoid arthritis --- carbonic anhydrase --- hedgehog --- cyclopamine --- small molecules --- acetazolamide --- motility --- metalloproteinases --- FAK --- cancer --- mucosal melanoma --- nivolumab --- pembrolizumab --- ipilimumab --- radiotherapy --- cholinergic system --- acetylcholine --- muscarinic receptors --- nicotinic receptors --- melanoma metastasis --- ShcD adaptor protein --- amoeboid motility --- Rac1 --- DOCK4 --- melanoma PDX --- target therapy --- cancer stem cells --- slow cycling phenotype --- drug resistance --- OXPHOS --- lipid metabolism --- cancer associated fibroblast --- melanomagenesis --- biomarkers --- checkpoint inhibitor --- PD-1 --- melanoma markers --- cytokines --- machine learning --- Support Vector Machine --- principal component analysis --- BCL2L10 --- STAT3 --- cytotoxicity --- survival --- ABT-737 --- Bcl-2 family --- ML258 --- HuR --- MITF --- metastases --- siRNA --- n/a
Listing 1 - 2 of 2 |
Sort by
|